Pfizer Inc (PFE) 31.28 $PFE
Would Merck Be the Best Buyer for AstraZeneca?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Pfizer has already been rejected by AstraZeneca twice, but rumors suggest Pfizer may be considering another, higher bid for the company. While adding AstraZeneca's diabetes and oncology pipeline would bulk-up Pfizer nicely, Merck & Co. ...
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Most active New York Stock Exchange-traded stocks
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
Pfizer-AstraZeneca Play Will Change the Global Pharma Landscape Forever
at The Street - Wed Apr 30, 2:10PM CDT
Will Pfizer succeed in its pursuit?
Big Pharma's Fall Slows the Dow's Momentum
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 30, 1:38PM CDT
The lack of surprises from today's Federal Open Market Committee meeting has the market on course for modest gains today, as the Dow Jones Industrial Average has gained about 30 points as of 2:30 p.m. EDT. However, most blue-chip members of the...
Why GlaxoSmithKline (GSK) Stock Is Down Today
at The Street - Wed Apr 30, 1:32PM CDT
Shares of GlaxoSmithKline (GSK) are lower as the healthcare group reported first quarter sales declined 10% as its main lung drug Advair grappled with an increasingly difficult U.S. market. CEO Andrew Witty all but ruled out a white knight bid for...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Global Non-Rhabdomyosarcoma Global Clinical Trials Review 2014
M2 - Wed Apr 30, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrg3gm/nonrhabdomyosarco) has announced the addition of the "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" report to their offering. Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - GlaxoSmithKline plc - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Zeltia, S.A. - Sarcoma Alliance for Research through Collaboration - Sanofi - Novartis AG - Merck & Co., Inc. - Amgen Inc. - National Cancer Institute - European Organization for Research and Treatment of Cancer - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Fred Hutchinson Cancer Research Center - Massachusetts General Hospital - Institut Bergonie - University of Michigan Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/mr...domyosarco
Early Glance: Pharmaceuticals companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Jim Cramer's Mad Dash: eBay's 'OK' Quarter
at The Street - Wed Apr 30, 9:41AM CDT
eBay's earnings report was OK but the company's repatriation of money doesn't make sense, Cramer says.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England).
'Mad Money' Lightning Round: Sysco Is Appealing
at The Street - Wed Apr 30, 5:00AM CDT
Cramer prefers Manitowoc over Middleby and sees Pfizer going higher.
Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
M2 - Wed Apr 30, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzslm9/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering. There has been an increase in awareness of bone education among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of osteoporosis drugs is expected to rise due to the increasing public awareness. This will probably result in increasing drug penetration. Raising general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as National Osteoporosis Awareness and Prevention Month every year. This has encouraged women and men to start conversations about bone health and family history as the first steps to protecting themselves and future generations from osteoporosis. Similarly, the National Osteoporosis Foundation is the leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life, and reducing human suffering, through programs of public and clinician awareness, education, advocacy, and research. These collaborations have helped to considerably increase the awareness about osteoporosis drugs. According to the report, one of the main drivers in this market is the increase in the global aging population. The number of patients suffering from osteoporosis is increasing owing to the increasing aging population both in developing and developed nations. The prevalence of osteoporosis and the incidence of osteoporotic fractures rise substantially with age, especially after the age of 50 years. Further, the report states that one of the main challenges is the multiple patent expiries. The shift toward lower-priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. Key vendors dominating this space are: - Amgen Inc - Eli Lilly & Co - Merck & Co. Inc. - Novartis AG. Other vendors mentioned in the report are: - Abiogen Pharma SpA - F. Hoffmann La Roche Ltd. - GlaxoSmithKline plc - Ligand Pharmaceuticals Inc. - NPS Pharma Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pzslm9/global
Jim Cramer's 'Mad Money' Recap: Don't Panic About Tech
at The Street - Tue Apr 29, 6:06PM CDT
Some similarities to the 2001 tech bubble exist, but Cramer says it's not time to head for the hills.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
Would Merck Be the Best Buyer for AstraZeneca?
Todd Campbell, The Motley Fool - Motley Fool - Wed Apr 30, 5:30PM CDT
Pfizer has already been rejected by AstraZeneca twice, but rumors suggest Pfizer may be considering another, higher bid for the company. While adding AstraZeneca's diabetes and oncology pipeline would bulk-up Pfizer nicely, Merck & Co. ...
Novartis' Zykadia Gets FDA Approval - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 5:10PM CDT
Novartis (NVS) received positive news when the U.S. Food and Drug Administration (FDA) approved Zykadia for the treatment of patients suffering from anaplastic lymphoma kinase-positive (ALK+) metastatic NSCLC.
Most active New York Stock Exchange-traded stocks
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — A look at New York Stock Exchange 10 most-active stocks at the close of trading:
Final Glance: Pharmaceuticals companies
AP - Wed Apr 30, 5:07PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
Will Mylan (MYL) Miss Q1 Earnings? - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Apr 30, 3:26PM CDT
Mylan (MYL) is set to report first quarter 2014 results on May 1 before the market opens.
Pfizer-AstraZeneca Play Will Change the Global Pharma Landscape Forever
at The Street - Wed Apr 30, 2:10PM CDT
Will Pfizer succeed in its pursuit?
Big Pharma's Fall Slows the Dow's Momentum
Dan Carroll, The Motley Fool - Motley Fool - Wed Apr 30, 1:38PM CDT
The lack of surprises from today's Federal Open Market Committee meeting has the market on course for modest gains today, as the Dow Jones Industrial Average has gained about 30 points as of 2:30 p.m. EDT. However, most blue-chip members of the...
Why GlaxoSmithKline (GSK) Stock Is Down Today
at The Street - Wed Apr 30, 1:32PM CDT
Shares of GlaxoSmithKline (GSK) are lower as the healthcare group reported first quarter sales declined 10% as its main lung drug Advair grappled with an increasingly difficult U.S. market. CEO Andrew Witty all but ruled out a white knight bid for...
Midday Glance: Pharmaceuticals companies
AP - Wed Apr 30, 1:12PM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
Global Non-Rhabdomyosarcoma Global Clinical Trials Review 2014
M2 - Wed Apr 30, 9:56AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mrg3gm/nonrhabdomyosarco) has announced the addition of the "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" report to their offering. Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2014" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies - Pfizer Inc. - GlaxoSmithKline plc - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Zeltia, S.A. - Sarcoma Alliance for Research through Collaboration - Sanofi - Novartis AG - Merck & Co., Inc. - Amgen Inc. - National Cancer Institute - European Organization for Research and Treatment of Cancer - Children's Oncology Group - Memorial Sloan Kettering Cancer Center - Fred Hutchinson Cancer Research Center - Massachusetts General Hospital - Institut Bergonie - University of Michigan Comprehensive Cancer Center For more information visit http://www.researchandmarkets.com/research/mr...domyosarco
Early Glance: Pharmaceuticals companies
AP - Wed Apr 30, 9:46AM CDT
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
Jim Cramer's Mad Dash: eBay's 'OK' Quarter
at The Street - Wed Apr 30, 9:41AM CDT
eBay's earnings report was OK but the company's repatriation of money doesn't make sense, Cramer says.
Pfizer Expects $100 Billion Grab for AstraZeneca to Boost Pipeline and Drop Tax Rate, an Industrial Info News Alert
Marketwire - Wed Apr 30, 5:31AM CDT
Reported by Annette Kreuger, Industrial Info Resources (Sugar Land, Texas) -- Despite a host of headaches, including steep patent losses and an industry in continual reorganization, Pfizer Incorporated (NYSE
FE) (New York, New York) has managed to remain one of the world's largest drug companies. With revenues of $51.6 billion in 2013, the company is now intent on spending at least $100 billion to snatch up AstraZeneca plc (NYSE:AZN) (London, England). 'Mad Money' Lightning Round: Sysco Is Appealing
at The Street - Wed Apr 30, 5:00AM CDT
Cramer prefers Manitowoc over Middleby and sees Pfizer going higher.
Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate
M2 - Wed Apr 30, 4:11AM CDT
Research and Markets (http://www.researchandmarkets.com/research/pzslm9/global) has announced the addition of the "Global Osteoporosis Drugs Market Opportunities with Forecasts to 2018: Amgen, Eli Lilly & Co, Merck & Co, Novartis Dominate" report to their offering. There has been an increase in awareness of bone education among patients and physicians. Enhanced patient and physician awareness is expected to lead to earlier disease diagnosis and treatment. The acceptability of osteoporosis drugs is expected to rise due to the increasing public awareness. This will probably result in increasing drug penetration. Raising general awareness about osteoporosis has led to an increase in research funding and support for clinical and support services. For instance, May is celebrated as National Osteoporosis Awareness and Prevention Month every year. This has encouraged women and men to start conversations about bone health and family history as the first steps to protecting themselves and future generations from osteoporosis. Similarly, the National Osteoporosis Foundation is the leading health organization dedicated to preventing osteoporosis and broken bones, promoting strong bones for life, and reducing human suffering, through programs of public and clinician awareness, education, advocacy, and research. These collaborations have helped to considerably increase the awareness about osteoporosis drugs. According to the report, one of the main drivers in this market is the increase in the global aging population. The number of patients suffering from osteoporosis is increasing owing to the increasing aging population both in developing and developed nations. The prevalence of osteoporosis and the incidence of osteoporotic fractures rise substantially with age, especially after the age of 50 years. Further, the report states that one of the main challenges is the multiple patent expiries. The shift toward lower-priced drugs will lead to a drop in the market valuations for that drug, reducing the overall market value. Key vendors dominating this space are: - Amgen Inc - Eli Lilly & Co - Merck & Co. Inc. - Novartis AG. Other vendors mentioned in the report are: - Abiogen Pharma SpA - F. Hoffmann La Roche Ltd. - GlaxoSmithKline plc - Ligand Pharmaceuticals Inc. - NPS Pharma Inc. - Pfizer Inc. For more information visit http://www.researchandmarkets.com/research/pzslm9/global
Jim Cramer's 'Mad Money' Recap: Don't Panic About Tech
at The Street - Tue Apr 29, 6:06PM CDT
Some similarities to the 2001 tech bubble exist, but Cramer says it's not time to head for the hills.
Celgene Deal Chief Calls Big Pharma Gutless For Lack of Biotech M&A
at The Street - Tue Apr 29, 3:26PM CDT
Some sharp opinions expressed by healthcare deal-makers at the Allicense 2014 conference.
